We invite feedback on the operation and impact of the human medicines and medical devices legislation as part of a statutory review required under the Medicines and Medical Devices Act 2021.
Similar Posts
Device specific vigilance guidance: Cardiac Implantable Electronic Devices (CIEDs)
Guidance for manufacturers of cardiac implantable electronic devices and their leads. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Guidance: Route B substantial modification pilot
Clinical trials Route B substantial modifications pilot starts on 1 October 2025. Prepare for the implementation of new regulations from 28 April 2026.
Healthcare regulator suggests simple winter wellness choices to keep you safe this cough and cold season
As the cold weather sets in and coughs and colds become more common, the MHRA is reminding people that small, everyday choices can make a big difference to winter wellbeing.
Medicines: Marketing Authorisation Holders’ submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing
Marketing Authorisation Holders should review their manufacturing processes to identify and, if found, to mitigate the risk of nitrosamine impurities being present.
Three convicted in major MHRA investigation into illegal online supply of medicines
Operation Lamborghini disrupts multimillion-pound criminal network supplying controlled drugs and unauthorised medicines online
Manufacturer’s Online Reporting Environment (MORE)
A digital platform designed to facilitate the reporting, monitoring, and management of medical device incidents.